Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia

Ramalingam, Thulasi Raman; Mohanraj, Selvaraj; Muthu, Anurekha; Prabhakar, Vikram; Balasubramaniam, R.; Vaidhyanathan, Lakshman; Easow, Jose; Raja, T

doi:10.1080/10428194.2021.1992621

Cited by 8 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As of March 2022, three new scores not included in our previous analysis have been published. [3][4][5] Their design and results align with previous efforts and examples of the above-mentioned inconsistencies can be found. For instance, Li et al 3 report CD5 sensitivity and CD43 specificity for CLL of 0.91 and 0.38, respectively, substantially different from other studies (>0.99 [6][7][8] and >0.9, 9,10 respectively), suggesting differences in cutoffs used for marker assessment (particularly for CD43), as well as in the application of the reference standard.…”

Section: Dear Editorssupporting

confidence: 70%

“…For instance, Li et al 3 report CD5 sensitivity and CD43 specificity for CLL of 0.91 and 0.38, respectively, substantially different from other studies (>0.99 [6][7][8] and >0.9, 9,10 respectively), suggesting differences in cutoffs used for marker assessment (particularly for CD43), as well as in the application of the reference standard. Ramalingam et al found a sensitivity CD20 dim for CLL of 0.96, 5 greater than the 0.85 reported by Zhu et al, 11 despite the fact that both used the same method (a receiver operating characteristic curve of median fluorescence intensity-MFI-values) to select the best cutoff. Furthermore, their score proposal includes CD20, CD200, CD45, and CD43 whilst Hoffmann et al 9 found an excellent performance by merely combining CD43 and CD200, again raising questions regarding the application of the reference standard.…”

Section: Dear Editorsmentioning

confidence: 85%

See 1 more Smart Citation

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Sorigué

Jurado

2022

Int J Lab Hematology

View full text Add to dashboard Cite

Section: Dear Editorssupporting

confidence: 70%

Section: Dear Editorsmentioning

confidence: 85%

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Sorigué

Jurado

2022

Int J Lab Hematology

View full text Add to dashboard Cite

“…Donor age was the most frequently assessed factor in the eligible studies. Of the 25 studies that reported the relationship between age and CD34 + cell yield 16 (64%) reported an association between age > 40 years and lower CD34 + cell yield (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Four further studies identified a non-significant trend towards this association (22)(23)(24)(25) whereas five studies reported no association (26)(27)(28)(29)(30).…”

Section: Agementioning

confidence: 99%

“…Higher pre-PBSC haemoglobin concentration (HB) was associated with higher CD34+ cell yield in two of the four studies that evaluated yield (8,25). Pre-PBSC HB was not associated with CD34+ cell concentration in two studies (17,33).…”

Section: Pre-pbsc Full Blood Count Parametersmentioning

confidence: 99%

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Peck,

Knapp-Wilson,

Burley

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There is a large inter-individual variation in CD34+ cell yield after G-CSF mobilisation and collection from peripheral blood in healthy allogenic haematopoietic stem cell donors. Donor characteristics including gender and age, baseline and precollection blood results, mobilisation factors and collection factors have been associated with CD34+ cell concentration in the blood after G-CSF mobilisation and/or CD34+ cell yield after collection. Since the literature reporting these associations is heterogeneous, we here clarify the determinants of CD34+ cell concentration and yield through a scoping literature review. Materials and Methods: MEDLINE, Embase, PubMed and Stem Cell Evidence were searched for studies published between 2000 and 2023. The inclusion criteria were studies of allogeneic donors undergoing G-CSF mobilisation and peripheral blood stem cell collection (PBSC). Eligible studies assessed an outcome of mobilisation or collection efficacy, indicated by the blood CD34+ cell concentration after 4 or 5 days of G-CSF treatment and/or CD34+ cell yield in the first PBSC collection after mobilisation. Included studies assessed associations between these outcomes and donor factors(such as age, gender, weight, ethnicity), mobilisation factors (G-CSF scheduling or dose), collection factors (venous access, processed blood volume) and laboratory factors (such as blood cell counts at baseline and after mobilisation). Results: The 51 eligible studies evaluated between 23 and 20,884 donors. 43 studies were retrospective, 32 assessed blood CD34+ cell concentration after mobilisation and 37 assessed CD34+ cell yield. In studies that recorded both outcomes, blood CD34+ cell concentration always predicted CD34+ cell yield. The most frequently assessed factor was donor age for which most studies reported that younger donors had a higher blood CD34+ cell concentration and CD34+ cell yield. Non-European ancestry was associated with both higher blood CD34+ cell concentration and yield although this finding was inconsistent. Conclusions: There remains poor consensus about the best predictors of blood CD34+ cell concentration and yield that requires further prospective study, particularly of the role of donor ancestry. The current focus on donor gender as a major predictor may require re-evaluation

show abstract

“…Moreover, the positive rate of CD43 was higher in CLL than in MCL. A recent study showed that CD43 and CD200 can differentiate CLL from non-CLL LPD with higher accuracy than the Matutes scoring system [ 63 , 72 ]. In addition, no difference in CD43 and CD200 expression has been observed between classic CLL and aCLL patients.…”

Section: Differential Diagnosis Of Atypical Cll With Other Lymphoprol...mentioning

confidence: 99%

Atypical Chronic Lymphocytic Leukemia—The Current Status

Robak,

Krawczyńska,

Cebula-Obrzut

et al. 2023

Cancers

View full text Add to dashboard Cite

A diagnosis of typical chronic lymphocytic leukemia (CLL) requires the presence of ≥5000 clonal B-lymphocytes/μL, the coexistence of CD19, CD20, CD5, and CD23, the restriction of light chain immunoglobulin, and the lack of expression of antigens CD22 and CD79b. Atypical CLL (aCLL) can be distinguished from typical CLL morphologically and immunophenotypically. Morphologically atypical CLL cells have been defined mainly as large, atypical forms, prolymphocytes, or cleaved cells. However, current aCLL diagnostics rely more on immunophenotypic characteristics rather than atypical morphology. Immunophenotypically, atypical CLL differs from classic CLL in the lack of expression of one or fewer surface antigens, most commonly CD5 and CD23, and the patient does not meet the criteria for a diagnosis of any other B-cell lymphoid malignancy. Morphologically atypical CLL has more aggressive clinical behavior and worse prognosis than classic CLL. Patients with aCLL are more likely to display markers associated with poor prognosis, including trisomy 12, unmutated IGVH, and CD38 expression, compared with classic CLL. However, no standard or commonly accepted criteria exist for differentiating aCLL from classic CLL and the clinical significance of aCLL is still under debate. This review summarizes the current state of knowledge on the morphological, immunophenotypic, and genetic abnormalities of aCLL.

show abstract

Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia

Cited by 8 publications

References 22 publications

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Atypical Chronic Lymphocytic Leukemia—The Current Status

Contact Info

Product

Resources

About